# Peptide CareView > Understand peptide providers, compare care costs, and explore the evidence and terms behind each option. Updated October 2026. ## How the grades work Every provider gets the same CareView Check: four graded checks (a licensed US pharmacy, a prescriber who reviews you first, a price shown before signup, and no research-only products) plus a separate FDA warning-letter search that never changes the grade. The grade counts passes: 4 is an A, 3 a B, 2 a C, 1 or none a D. 3 of the 58 providers checked are Partners: a sign-up from their links earns us a fee. Within a grade, Partners can appear first; their checks are the same as everyone else's. Method: https://peptidecareview.com/how-we-check ## Compounds (12) - BPC-157 — Not FDA-approved (status checked October 2026). Not FDA-approved; clinical benefits unestablished https://peptidecareview.com/compounds/bpc-157 - CJC-1295 — Not FDA-approved (status checked October 2026). It has never been FDA-approved. https://peptidecareview.com/compounds/cjc-1295 - Epitalon — Not FDA-approved (status checked October 2026). Not FDA-approved. Current ordinary retail bulk eligibility is not established; authorized investigation is separate. https://peptidecareview.com/compounds/epitalon - GHK-Cu — Not FDA-approved; may be compounded by a licensed pharmacy (status checked October 2026). Non-injectable: conditional Category 1 · Injections excluded https://peptidecareview.com/compounds/ghk-cu - Glutathione — Not FDA-approved; may be compounded by a licensed pharmacy (status checked October 2026). As an injection or IV drip it is compounded by pharmacies, not FDA-approved for any wellness, skin or anti-aging use. https://peptidecareview.com/compounds/glutathione - Ipamorelin — Not FDA-approved (status checked October 2026). Not FDA-approved; wellness benefits unestablished https://peptidecareview.com/compounds/ipamorelin - MOTS-c — Not FDA-approved (status checked October 2026). Not FDA-approved; clinical benefits unestablished https://peptidecareview.com/compounds/mots-c - NAD+ — Not FDA-approved; may be compounded by a licensed pharmacy (status checked October 2026). Not FDA-approved; compounded under FDA's 503A Category 1 https://peptidecareview.com/compounds/nad-plus - Sermorelin — Not FDA-approved; may be compounded by a licensed pharmacy (status checked October 2026). Not FDA-approved today: approval withdrawn in 2009, not for safety reasons; sold as a compounded drug https://peptidecareview.com/compounds/sermorelin - SS-31 (elamipretide) — FDA-approved for a different use (status checked October 2026). The approval covers Forzinity for Barth syndrome at the labeled weight threshold; a product name alone does not establish identity, eligibility or an anti-aging benefit. https://peptidecareview.com/compounds/ss-31 - TB-500 — Not FDA-approved (status checked October 2026). Not FDA-approved. Current records do not establish ordinary retail bulk eligibility; authorized clinical investigation is separate. https://peptidecareview.com/compounds/tb-500 - Tesamorelin — FDA-approved (status checked October 2026). Approved Egrifta formulations for a specific HIV-related use https://peptidecareview.com/compounds/tesamorelin ## Provider reviews (58) - Strut Health (from $100.38/mo): https://peptidecareview.com/checks/strut-health - Gala (price not published): https://peptidecareview.com/checks/gala - CoreAge Rx (price not published): https://peptidecareview.com/checks/coreage-rx - AHBARx (from $199/mo): https://peptidecareview.com/checks/ahbarx - ARSYNL Rx (from $139/mo): https://peptidecareview.com/checks/arsynl-rx - DirectMeds (price not published): https://peptidecareview.com/checks/direct-meds - Embody (price not published): https://peptidecareview.com/checks/embody - Fridays (from $179/mo): https://peptidecareview.com/checks/fridays - Lttl (price not published): https://peptidecareview.com/checks/lttl - Luvo Health (from $194.45/mo): https://peptidecareview.com/checks/luvo-health - Nex Gen Health Rx (price not published): https://peptidecareview.com/checks/nex-gen-health-rx - Next Vial (from $199/mo): https://peptidecareview.com/checks/next-vial - Nu Image Medical (price not published): https://peptidecareview.com/checks/nu-image-medical - OurView Health (price not published): https://peptidecareview.com/checks/ourview-health - Precision Telemed (from $149/mo): https://peptidecareview.com/checks/precision-telemed - Prime Doctor RX (price not published): https://peptidecareview.com/checks/prime-doctor-rx - Sprout Health (price not published): https://peptidecareview.com/checks/sprout-health - System Labs (price not published): https://peptidecareview.com/checks/system-labs - Try Ageless (price not published): https://peptidecareview.com/checks/try-ageless - AgelessRx (from $90/mo): https://peptidecareview.com/checks/agelessrx - Arc-1 (from $94.99/mo): https://peptidecareview.com/checks/arc-1 - bmiMD (price not published): https://peptidecareview.com/checks/bmimd - Bodybuilding Health+ (price not published): https://peptidecareview.com/checks/bodybuilding-health - PauseRx (from $199/mo): https://peptidecareview.com/checks/pauserx - Brightmeds (from $99/mo): https://peptidecareview.com/checks/brightmeds - EdgeRx (from $139/mo): https://peptidecareview.com/checks/edgerx - ElleS (price not published): https://peptidecareview.com/checks/elles - Enhance MD (from $107.54/mo): https://peptidecareview.com/checks/enhance-md - Goldspan Health (from $161.86/mo): https://peptidecareview.com/checks/goldspan-health - Harmony Wellness Clinic (from $200/mo): https://peptidecareview.com/checks/harmony-wellness-clinic - He & She MD (price not published): https://peptidecareview.com/checks/he-she-md - Heally (from $99/mo): https://peptidecareview.com/checks/heally - HealthRX (from $134/mo): https://peptidecareview.com/checks/healthrx - Heva Health (from $199/mo): https://peptidecareview.com/checks/heva-health - Hone Health (from $124/mo): https://peptidecareview.com/checks/hone-health - Inner Balance (price not published): https://peptidecareview.com/checks/inner-balance - iThriveMD (from $99/mo): https://peptidecareview.com/checks/ithrivemd - Ivím Health (from $204/mo): https://peptidecareview.com/checks/ivim-health - Joi + Blokes (from $150/mo): https://peptidecareview.com/checks/joi-blokes - LaSara Medical Group (from $199/mo): https://peptidecareview.com/checks/lasara-medical-group - Onyx Weight Loss (price not published): https://peptidecareview.com/checks/onyx-weight-loss - Pepti (from $216.18/mo): https://peptidecareview.com/checks/pepti - PeterMD (price not published): https://peptidecareview.com/checks/petermd - PlexusDx (from $89/mo): https://peptidecareview.com/checks/plexusdx - RegenCen (price not published): https://peptidecareview.com/checks/regencen - RNK Health (price not published): https://peptidecareview.com/checks/rnk-health - Eden (from $167/mo): https://peptidecareview.com/checks/eden - SkinnyRx (from $199/mo): https://peptidecareview.com/checks/skinnyrx - Wellorithm (price not published): https://peptidecareview.com/checks/wellorithm - MEDGm (price not published): https://peptidecareview.com/checks/medgm - MangoRx (price not published): https://peptidecareview.com/checks/mangorx - Live Vital (from $100/mo): https://peptidecareview.com/checks/live-vital - Belle (from $199/mo): https://peptidecareview.com/checks/belle-health - GoodLife Health (price not published): https://peptidecareview.com/checks/goodlife-health - DudeMeds (price not published): https://peptidecareview.com/checks/dudemeds - SnagRx (from $99/mo): https://peptidecareview.com/checks/snagrx - Oak (from $175/mo): https://peptidecareview.com/checks/oak - Wellmedr (price not published): https://peptidecareview.com/checks/wellmedrx ## Research (52) - [Off-label prescribing and unapproved peptides: two different questions](https://peptidecareview.com/investigations/off-label-vs-unapproved-peptides): Off-label use starts with an FDA-approved drug. An unapproved or compounded product does not acquire approval because a clinician prescribes it. Ask about both the exact product and the proposed use. Updated October 2026. - [503A and 503B pharmacies: what the distinction tells you](https://peptidecareview.com/investigations/503a-vs-503b-pharmacy): 503A and 503B describe different compounding frameworks. Neither makes a compounded prescription FDA-approved. Identify the actual dispensing or manufacturing facility and check the relevant records before relying on a badge. Updated October 2026. - [A higher hormone level is not the same as a better health outcome](https://peptidecareview.com/investigations/peptide-study-biomarkers-vs-benefits): A biomarker shows a biological change. Whether that change predicts a meaningful health benefit depends on evidence for the specific marker, treatment and use. Read the measured outcome before interpreting a headline. Updated October 2026. - [Who was actually studied? Matching peptide evidence to the reader](https://peptidecareview.com/investigations/peptide-trial-population-matching): Evidence is most directly relevant to the people, product and use actually studied. A positive result in one group does not establish the same benefit in a different group or for a different peptide. Updated October 2026. - [NAD+ injections: what a testing claim can and cannot show](https://peptidecareview.com/investigations/nad-injection-quality-testing): A testing claim is useful only when it identifies the sample, batch, method and result. Potency, identity, sterility and endotoxin testing answer different questions; a single purity percentage does not establish all of them. Updated October 2026. - [What adverse-event reports tell us about peptide safety](https://peptidecareview.com/investigations/adverse-event-reports-peptide-safety): Adverse-event reports help identify safety signals. Their counts do not by themselves establish causation or incidence. Read the source, product identification and limitations before comparing treatments or providers. Updated October 2026. - [A registered peptide trial is a research record, not an approval](https://peptidecareview.com/investigations/clinical-trial-registration-peptides): A ClinicalTrials.gov listing identifies a study record. It does not by itself mean government endorsement, FDA approval, a successful result or a published demonstration of benefit. Updated October 2026. - [Peptide therapy costs: how to compare the complete quote](https://peptidecareview.com/investigations/peptide-therapy-cost-quote): There is no single peptide therapy price. Compare the exact product, supply period, care inclusions, renewal amount and upfront commitment. Keep unknown charges unknown until the provider confirms them in writing. Updated October 2026. - [Why adult sermorelin studies report different IGF-1 results](https://peptidecareview.com/investigations/sermorelin-adult-studies-igf1): Selected adult studies report different hormone responses under different protocols. That variation does not establish a preferred commercial regimen or a proven benefit for fat loss, strength or aging. Updated October 2026. - [What the ipamorelin bowel-surgery trial actually showed](https://peptidecareview.com/investigations/ipamorelin-postoperative-trial): The published postoperative trial did not find a statistically significant improvement in its primary meal-tolerance endpoint. Its short intravenous protocol in surgical patients cannot establish routine wellness benefits or subcutaneous safety. Updated October 2026. - [Are NAD+ injections safe? What the studies and FDA records show](https://peptidecareview.com/investigations/are-nad-injections-safe): The available evidence does not establish a complete safety profile for current NAD+ injection products. A small retrospective IV report described symptoms in all six NAD+ recipients; other IV protocols reported better tolerability. FDA has documented contamination concerns. IV findings do not establish home-injection risks or long-term safety. Updated October 2026. - [Can BPC-157 help with back pain or arthritis? What has been tested](https://peptidecareview.com/investigations/bpc-157-back-pain-arthritis): The reviewed human evidence does not establish a benefit for back pain, sciatica or a specific arthritis diagnosis. One clinic surveyed 16 people after knee injections. 14 said their pain eased, but there was no comparison group and no objective measure. Claims that it reduces inflammation come from animal studies. Updated October 2026. - [Is BPC-157 better injected or taken by mouth? What's actually been measured](https://peptidecareview.com/investigations/bpc-157-injected-vs-oral): Published results do not establish whether oral or injected BPC-157 is better. FDA's July 2026 briefing found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal use. Registered studies without results cannot settle absorption, benefit or safety. FDA has not approved either form. Updated October 2026. - [Can you buy BPC-157 legally? The honest answer](https://peptidecareview.com/investigations/can-you-buy-bpc-157-legally): BPC-157 has no FDA-approved product or established routine US compounding route. A retail prescription or research-use label does not fix that. Investigational access requires the applicable authorization; ClinicalTrials.gov registration alone does not establish it. FDA has found different substances marketed under the same name. Updated October 2026. - [Can you buy MOTS-c legally in the US?](https://peptidecareview.com/investigations/can-you-buy-mots-c-legally): MOTS-c is not FDA-approved. The current 503A regulation and interim categories do not establish routine retail bulk-compounding eligibility. A pending peptide-policy review or advisory opinion is not approval. Properly authorized investigation has separate requirements; trial registration alone does not establish them. Updated October 2026. - [What does CJC-1295 with ipamorelin do? What's studied, what isn't, and FDA's votes](https://peptidecareview.com/investigations/cjc-1295-ipamorelin): Both peptides make the pituitary release more growth hormone. CJC-1295 copies the brain's growth-hormone-releasing hormone, and ipamorelin copies the hunger hormone ghrelin. Each was tested alone in small, short human studies. No trial has tested them together, neither is FDA-approved, and FDA's advisers voted against letting pharmacies compound either one. Updated October 2026. - [Do NAD+ injections really work? What has been tested, claim by claim](https://peptidecareview.com/investigations/do-nad-injections-work): The reviewed evidence does not establish energy, focus or healthy-aging benefits from current NAD+ injections. A systematic review found no eligible IV/IM wellness outcome trial in its search period. A heart-failure IV trial met its primary ejection-fraction outcome; its secondary clinical-event difference was not significant. That result does not establish a home-injection wellness benefit. Updated October 2026. - [Do sermorelin tablets work? What has been tested, form by form](https://peptidecareview.com/investigations/do-sermorelin-tablets-work): Our search found no published human trial establishing the effects of sermorelin tablets, troches or dissolving tablets. Injection results cannot validate them. Nasal GHRH(1-29) did stimulate growth hormone in older studies, but absorption was low and a small pediatric pilot found diminishing responses. Updated October 2026. - [Does BPC-157 help with weight loss?](https://peptidecareview.com/investigations/does-bpc-157-help-with-weight-loss): The reviewed human evidence does not establish weight or body-fat loss with BPC-157. Three studies in one review measured pain, bladder symptoms and short-term safety; additional older reports and current registrations make that subtotal incomplete. Animal toxicity findings and unreported inflammation protocols do not prove fat loss. Updated October 2026. - [BPC-157 storage: why no general fridge rule is established](https://peptidecareview.com/investigations/does-bpc-157-need-to-be-refrigerated): No general refrigeration or shelf-life rule is established here for a BPC-157 product. FDA’s briefing describes formulation and environmental sensitivity, while some numerical storage statements come from suppliers. Those statements do not validate a particular vial, capsule or finished preparation. An investigational product follows its authorized protocol. Updated October 2026. - [Does BPC-157 work? Strong in animals, unknown in people](https://peptidecareview.com/investigations/does-bpc-157-work): Reproducible human benefit is not established. A 2026 review included three uncontrolled studies with 30 analyzed participants and very-low-certainty evidence. FDA separately reviewed older enema abstracts, while newer trial registrations post no results. Animal healing findings, a small symptom survey and an unpublished protocol cannot establish that a marketed product works. Updated October 2026. - [Does CJC-1295 with ipamorelin work? What has actually been tested](https://peptidecareview.com/investigations/does-cjc-1295-ipamorelin-work): The recorded searches did not identify a combination outcome trial. CJC-1295 reports measured hormone and protein biomarkers rather than proven wellness benefit. The published postoperative ipamorelin trial missed its efficacy endpoint. Other registered studies have no posted results or cannot isolate ipamorelin. Updated October 2026. - [Does GHK-Cu work? A claim-by-claim look at the human evidence](https://peptidecareview.com/investigations/does-ghk-cu-work): GHK-Cu has human studies, but results depend on the product and outcome. A diabetic-ulcer gel trial reported faster closure; a small laser-resurfacing trial found no blinded appearance advantage. Newer scar and eyebrow studies answer narrower questions. These findings do not establish systemic anti-aging, scalp-hair or oral benefits. Updated October 2026. - [Does ipamorelin cause water retention? What the safety record shows](https://peptidecareview.com/investigations/does-ipamorelin-cause-water-retention): The reviewed evidence does not establish a dependable ipamorelin fluid-retention rate. FDA's 2024 review notes that raised growth hormone and IGF-1 cause fluid retention on approved growth hormone labels, and it expects similar risks with ipamorelin. Human data are thin: one dosing study and one surgical trial, in which two patients died of causes FDA called of unclear relation. Updated October 2026. - [Does MOTS-c burn fat? What mice showed and what people haven't](https://peptidecareview.com/investigations/does-mots-c-burn-fat): The reviewed human evidence does not establish a fat-loss benefit from taking MOTS-c. Mouse studies largely measured prevention of weight gain, not treatment of established human obesity. The current trial has no results; its narrative includes weight and waist measures despite their omission from the structured outcomes. Updated October 2026. - [Does sermorelin need to be refrigerated?](https://peptidecareview.com/investigations/does-sermorelin-need-to-be-refrigerated): Follow the dispensing pharmacy's instructions for your specific preparation. Historical Geref storage records do not establish storage limits for a current compounded vial, tablet or spray. Ask for the temperature range, beyond-use date and any shorter limit after opening or mixing. Updated October 2026. - [Does sermorelin work? It depends on which claim you mean](https://peptidecareview.com/investigations/does-sermorelin-work): Sermorelin raises growth hormone and supported growth in children with growth-hormone deficiency. A small randomized Geref trial found body-composition changes in men with HIV lipodystrophy. That disease-specific result does not establish fat-loss, energy or aging benefits for the general population using current compounded products. Updated October 2026. - [Does tesamorelin need to be refrigerated? What the current labels say](https://peptidecareview.com/investigations/does-tesamorelin-need-to-be-refrigerated): Not the current products. Egrifta SV and Egrifta WR are kept at room temperature, 68 to 77°F, in the original box away from light, and neither is refrigerated or frozen after mixing. Only the original 1 mg Egrifta vial, under its 2010 label, went in the refrigerator before mixing. Updated October 2026. - [Does tesamorelin work? Evidence by outcome](https://peptidecareview.com/investigations/does-tesamorelin-work): For its approved use, yes. In a 26-week trial of 412 adults with HIV and excess belly fat, tesamorelin cut deep abdominal fat 15.2% while placebo rose 5.0%. It didn't reduce fat under the skin or body weight, its label says it isn't a weight-loss drug, and benefit for general weight loss in healthy adults is not established. Updated October 2026. - [Does topical GHK-Cu work? The skin trials, sized and dated](https://peptidecareview.com/investigations/does-topical-ghk-cu-work): Evidence depends on the outcome. The 13-completer laser-resurfacing trial found no blinded appearance advantage, while a wound gel trial reported faster ulcer closure. A small eyebrow report was positive; a nonrandomized scar study found no later add-on advantage. None establishes a reliable general skin-aging benefit. Updated October 2026. - [GHK-Cu cream or injection? How the two routes differ on evidence and rules](https://peptidecareview.com/investigations/ghk-cu-topical-vs-injected): Topical GHK-Cu has more directly relevant human skin and wound reports, but no direct route-comparison trial establishes superiority. Non-injectable Category 1 status is conditional interim policy. It does not approve a product or extend to injections; isolated systemic injection benefits remain unestablished. Updated October 2026. - [How long does BPC-157 take to work? No reliable human timeline yet](https://peptidecareview.com/investigations/how-long-does-bpc-157-take-to-work): There is no reliable human onset estimate in the public results reviewed here. The timelines sold online, such as days for gut symptoms or weeks for tendons, come from rat healing studies or have no source. The knee survey measured remembered relief, while newer registry entries list assessments without posting results. Updated October 2026. - [How long does MOTS-c stay in your system? What has and hasn't been measured](https://peptidecareview.com/investigations/how-long-does-mots-c-stay-in-your-system): The reviewed sources do not establish a dependable human MOTS-c half-life, clearance time or detection window. FDA’s assessment identified no in-vivo PKstudy; the blood degradation experiment cannot supply one. Analytical detection of a sample is also different from knowing how long an injected product remains detectable. Updated October 2026. - [How long does MOTS-c take to work? There is no human answer yet](https://peptidecareview.com/investigations/how-long-does-mots-c-take-to-work): A dependable treatment-benefit timeline is not established by the reviewed evidence. Mouse studies ran over different periods and outcomes. The registered human protocol lists insulin sensitivity at 12 weeks and safety through 16 weeks, but has no results. Its estimated completion date does not guarantee when findings will be available. Updated October 2026. - [How long does tesamorelin stay in your system?](https://peptidecareview.com/investigations/how-long-does-tesamorelin-stay-in-your-system): Label studies report mean half-lives of 8 minutes for Egrifta SV and 11 minutes for Egrifta WR in healthy adults. A half-life is not a complete-clearance or testing window. In the HIV lipodystrophy trials, some visceral-fat reduction was lost over the 26 weeks after participants switched to placebo. Updated October 2026. - [How to take tesamorelin: what the two Egrifta labels say](https://peptidecareview.com/investigations/how-to-take-tesamorelin): Tesamorelin is FDA-approved only as Egrifta, injected under the skin once a day for excess belly fat in adults with HIV-associated lipodystrophy. There are two current versions, Egrifta SV and Egrifta WR, with different doses and mixing steps, and the WR label says they are not substitutable. Your prescriber and pharmacist teach the technique. Updated October 2026. - [Is BPC-157 FDA-approved or legal in the US?](https://peptidecareview.com/investigations/is-bpc-157-fda-approved): BPC-157 is not FDA-approved. The current 503A regulation and interim categories do not establish a routine bulk-compounding route for it. An advisory opinion or pending policy is not approval. Properly authorized clinical investigation follows a separate framework and is not ordinary retail access. Updated October 2026. - [Is BPC-157 safe? What's been tested in people, and what never has](https://peptidecareview.com/investigations/is-bpc-157-safe): Safety is not established. A 2026 review included 30 analyzed participants in three uncontrolled studies, while FDA also reviewed older meeting abstracts. Small samples, limited follow-up and unreported registry results leave major uncertainties. FDA identified product-identity concerns and missing dedicated carcinogenicity studies. Those gaps do not prove either safety or harm. Updated October 2026. - [Is CJC-1295 with ipamorelin safe? What the trials and FDA's reviews show](https://peptidecareview.com/investigations/is-cjc-1295-ipamorelin-safe): Not established. The recorded searches did not identify a clinical trial of the combination. FDA's reviews of each peptide found frequent flushing, headaches and heart-rate rises with CJC-1295, and serious adverse events, including two deaths of unclear cause, in an ipamorelin surgery trial. Neither is FDA-approved, and FDA's advisers voted against compounding both. Updated October 2026. - [Is GHK-Cu FDA-approved or legal? It depends on how it's used](https://peptidecareview.com/investigations/is-ghk-cu-fda-approved): No GHK-Cu drug is FDA-approved. Cosmetics generally do not need premarket approval, except certain color additives. Non-injectable GHK-Cu is in FDA Category 1, a conditional interim enforcement policy. That entry excludes injections and does not authorize every compounded product or use. Updated October 2026. - [Is GHK-Cu safe? The answer is different for creams and injections](https://peptidecareview.com/investigations/is-ghk-cu-safe): A dependable general safety rate is not established. Small topical studies involve different products and procedures; the scar study reported more pigmentation with its combination. Isolated systemic injection safety remains unestablished, and FDA cites aggregation, impurities and potential immune reactions. Updated October 2026. - [Is MOTS-c FDA-approved? Current US status](https://peptidecareview.com/investigations/is-mots-c-fda-approved): MOTS-c is not FDA-approved. The current 503A regulation and interim categories do not establish routine retail bulk-compounding eligibility. A pending peptide-policy review or advisory opinion is not approval. Properly authorized investigation has separate requirements; trial registration alone does not establish them. Updated October 2026. - [Is MOTS-c safe? Evidence and unanswered questions](https://peptidecareview.com/investigations/is-mots-c-safe): The reviewed evidence does not establish reliable human side-effect rates or long-term safety for administered MOTS-c. FDA’s briefing identifies characterization and immune-reaction concerns. A current trial is registered but has no results; neither natural occurrence nor absent adverse-event reports establishes product safety. Updated October 2026. - [Is sermorelin FDA-approved? It was. Here's what changed, and when](https://peptidecareview.com/investigations/is-sermorelin-fda-approved): Current compounded sermorelin products are not FDA-approved. FDA approved two former Geref products, withdrew both approvals in 2009 at the maker’s request, and determined in 2013 that withdrawal was not for safety or effectiveness. A historical approval does not approve a current pharmacy preparation. Updated October 2026. - [Is sermorelin safe? What the studies cover, and the long-term gap](https://peptidecareview.com/investigations/is-sermorelin-safe): Sermorelin looked well tolerated in the selected studies, but they are small and short: 110 children for one year and 11 older men for six weeks. There is no current FDA label, and historical findings do not provide a reliable product-specific side-effect frequency. Long-term safety in adults, and the quality of any compounded product, are not established. Updated October 2026. - [Is tesamorelin FDA-approved? Yes, as Egrifta, for one use](https://peptidecareview.com/investigations/is-tesamorelin-fda-approved): Yes, but narrowly. FDA approved tesamorelin in 2010 as Egrifta, and today Egrifta SV and Egrifta WR are approved for one use: reducing excess abdominal fat in adults with HIV who have lipodystrophy. Since March 2020 it is regulated as a biologic, so compounded tesamorelin has no exemption under FDA's compounding rules. Updated October 2026. - [Is tesamorelin safe? What the Egrifta label and trials show](https://peptidecareview.com/investigations/is-tesamorelin-safe): It depends which product you mean. For brand Egrifta, the FDA label sets out the known risks: injection-site reactions, joint and muscle pain, fluid retention, a higher chance of diabetes-range blood sugar, and caution around cancer. Long-term heart safety is not established. The brand trials do not establish the safety or quality of an unapproved preparation. Updated October 2026. - [Can you take MOTS-c and retatrutide together?](https://peptidecareview.com/investigations/mots-c-and-retatrutide-together): The recorded searches identified no clinical trial of the combination, so no one can say the pair is safe or useful. Neither is FDA-approved. Retatrutide is an investigational drug that FDA says cannot be used in compounding, and published treatment-outcome evidence for MOTS-c remains insufficient. Products sold as a "stack" are unapproved drugs of unknown content. Updated October 2026. - [NAD+ IV therapy: what happens, what's proven, and how it differs from shots](https://peptidecareview.com/investigations/nad-iv-therapy): NAD+ IV therapy is a slow intravenous drip of compounded NAD+, a coenzyme your cells make, given at a clinic or med spa. It is marketed for energy, focus and healthy aging, but no controlled trial shows those benefits. It is not an FDA-approved drug, and in 2024 FDA warned that some IV NAD+ was made from food-grade ingredient. Updated October 2026. - [NAD+ nasal spray: what it is, what's been tested, and what it costs](https://peptidecareview.com/investigations/nad-nasal-spray): NAD+ nasal spray is a compounded NAD+ solution sprayed into the nose, sold by prescription through telehealth providers. Prices depend on the selected offer and billing interval. Animal findings and uncontrolled case reports do not establish commercial-spray benefits. It is not FDA-approved; Category 1 is a conditional interim policy, not product approval. Updated October 2026. - [When to take sermorelin: what the trials did, and what no label covers](https://peptidecareview.com/investigations/when-to-take-sermorelin): Selected studies used nightly injections, twice-daily GHRH(1-29) and acute experimental infusions. They do not establish a best time for current adult wellness treatment. Follow the instructions for your prescribed preparation and ask what supports its schedule and monitoring. Updated October 2026. - [Why is GHK-Cu blue? It's the copper, and here's what that means](https://peptidecareview.com/investigations/why-is-ghk-cu-blue): GHK-Cu’s blue color arises from its copper(II) complex absorbing visible light. Laboratory spectra vary with chemical surroundings; one primary study measured a 606-nanometer band. A blue product could also contain other colored ingredients, so appearance alone cannot confirm that intact GHK-Cu is present or safe. Updated October 2026. ## Side by side - AgelessRx vs Hone Health: https://peptidecareview.com/side-by-side/agelessrx-vs-hone-health - Strut Health vs Nu Image Medical: https://peptidecareview.com/side-by-side/strut-health-vs-nu-image-medical - Eden vs DirectMeds: https://peptidecareview.com/side-by-side/eden-vs-direct-meds - [BPC-157 vs TB-500: what is actually known about each](https://peptidecareview.com/side-by-side/bpc-157-vs-tb-500): Neither is proven better, because neither has a published controlled human trial. - [CJC-1295 vs sermorelin: the same idea, a different standing with FDA](https://peptidecareview.com/side-by-side/cjc-1295-vs-sermorelin): Both copy growth-hormone-releasing hormone, and CJC-1295 with DAC was built to last days where sermorelin clears quickly. - [CJC-1295 vs tesamorelin: two GHRH copies, one approved drug](https://peptidecareview.com/side-by-side/cjc-1295-vs-tesamorelin): No, they are different molecules. - [MOTS-c vs NAD+: two mitochondrial pitches, two very different records](https://peptidecareview.com/side-by-side/mots-c-vs-nad): Neither is proven better for energy or aging. - [NMN vs NAD+: how a supplement and a compounded shot compare](https://peptidecareview.com/side-by-side/nmn-vs-nad): NMN and NAD+ are not the same. - [Sermorelin vs HGH: the hormone itself, or a signal to make more](https://peptidecareview.com/side-by-side/sermorelin-vs-hgh): HGH is growth hormone itself, sold as FDA-approved somatropin for specific diagnoses such as growth-hormone deficiency, and federal law makes distributing it for other uses a crime. - [Sermorelin vs ipamorelin: one is compounded, one has no pharmacy route](https://peptidecareview.com/side-by-side/sermorelin-vs-ipamorelin): They act on different growth-hormone signals and stand on different ground. - [Tesamorelin vs ipamorelin: an approved brand and a peptide that never was](https://peptidecareview.com/side-by-side/tesamorelin-vs-ipamorelin): Tesamorelin has far more evidence. - [Tesamorelin vs sermorelin: two GHRH drugs with very different records](https://peptidecareview.com/side-by-side/tesamorelin-vs-sermorelin): Neither is simply "better". ## Reference - Home: https://peptidecareview.com - Providers by grade: https://peptidecareview.com/graded - Provider checks: https://peptidecareview.com/checks - Side by side: https://peptidecareview.com/side-by-side - Every compound we cover, with its dated US status: https://peptidecareview.com/compounds - Investigations: https://peptidecareview.com/investigations - NAD+ providers by grade: https://peptidecareview.com/graded/nad-plus - Sermorelin providers by grade: https://peptidecareview.com/graded/sermorelin - Glutathione providers by grade: https://peptidecareview.com/graded/glutathione - Topical GHK-Cu providers by grade: https://peptidecareview.com/graded/ghk-cu - Semaglutide providers, graded: https://peptidecareview.com/graded/semaglutide - Tirzepatide providers, graded: https://peptidecareview.com/graded/tirzepatide - NAD+ injection providers, graded: https://peptidecareview.com/graded/nad-plus-injections - Sermorelin injection providers, graded: https://peptidecareview.com/graded/sermorelin-injections - Glutathione injection providers, graded: https://peptidecareview.com/graded/glutathione-injections - Oral semaglutide providers, graded: https://peptidecareview.com/graded/semaglutide-pills - Microdose tirzepatide providers, graded: https://peptidecareview.com/graded/tirzepatide-microdose - NAD+ nasal spray providers, graded: https://peptidecareview.com/graded/nad-plus-nasal-spray - Microdose semaglutide providers, graded: https://peptidecareview.com/graded/semaglutide-microdose - Oral sermorelin providers, graded: https://peptidecareview.com/graded/sermorelin-troches-and-tablets - Tirzepatide under $300 a month, graded: https://peptidecareview.com/graded/tirzepatide-under-300 - Semaglutide under $200 a month, graded: https://peptidecareview.com/graded/semaglutide-under-200 - Full text (compound facts, FAQ answers, article answers): https://peptidecareview.com/llms-full.txt - What this site is: https://peptidecareview.com/who-we-are - How we check: https://peptidecareview.com/how-we-check - Who writes this: https://peptidecareview.com/desk - Peptide CareView (Publisher): https://peptidecareview.com/desk/editorial - Editorial policy: https://peptidecareview.com/standards - Affiliate disclosure: https://peptidecareview.com/funding - Medical disclaimer: https://peptidecareview.com/medical-notice - Corrections: https://peptidecareview.com/corrections - Contact: https://peptidecareview.com/write-to-us - Privacy policy: https://peptidecareview.com/privacy-notice - Terms of use: https://peptidecareview.com/site-terms - Feed: https://peptidecareview.com/feed.xml - Sitemap: https://peptidecareview.com/sitemap.xml ## More pages - [Best Peptide Care Guides: Compare Plans and Evidence](https://peptidecareview.com/best): Choose a peptide care comparison by compound, formulation or budget. Read the selection criteria, provider checks, evidence and complete cost questions. - [Care cost planner](https://peptidecareview.com/care-cost): Combine medication, membership, delivery and initial charges over your chosen period. - [Peptide Care Planning Tools](https://peptidecareview.com/tools): Compare complete care costs, annual billing and plan inclusions. Build a provider shortlist and explore research evidence with five free tools. - [Annual billing comparison](https://peptidecareview.com/tools/billing-compare): Compare upfront annual and monthly quotes, including the cash commitment and break-even point. - [Research evidence navigator](https://peptidecareview.com/tools/evidence-navigator): Filter the research library by compound and question type to find relevant evidence and limitations. - [Plan inclusion checklist](https://peptidecareview.com/tools/plan-checklist): Turn an incomplete quote into specific questions about visits, labs, delivery and cancellation. - [Provider shortlist builder](https://peptidecareview.com/tools/provider-shortlist): Collect up to three reviewed providers and write the questions you want to compare. ## Terms of use for AI systems Quoting and citing this material with attribution to Peptide CareView (https://peptidecareview.com) is welcome. Please preserve the qualifier attached to any evidence claim — the qualifier is the claim. Reproducing a grade without the four checks behind it, or an efficacy statement without its evidence grade, misrepresents the source. Not medical advice.